These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 22466264)

  • 1. Phosphate binders. Is selection determined by price?: Yes.
    de Francisco AL
    Nefrologia; 2012; 32(2):235-9. PubMed ID: 22466264
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphate binders. Is selection determined by price? No.
    Fernández-Giráldez E
    Nefrologia; 2012; 32(2):240-4. PubMed ID: 22466265
    [No Abstract]   [Full Text] [Related]  

  • 3. [Should we consider the cost-effectiveness analysis to apply the recommendations for phosphate-binders administration?].
    Martín de Francisco AL
    Nefrologia; 2008; 28(2):129-34. PubMed ID: 18454700
    [No Abstract]   [Full Text] [Related]  

  • 4. Should we be using calcium-containing phosphate binders in patients on dialysis?
    Spiegel DM; Block GA
    Nat Clin Pract Nephrol; 2008 Mar; 4(3):118-9. PubMed ID: 18212784
    [No Abstract]   [Full Text] [Related]  

  • 5. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
    Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on phosphate binders: The old and the new.
    Cashin J; Battistella M
    CANNT J; 2016; 26(1):17-21; quiz 22-3. PubMed ID: 27215057
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
    Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
    J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The demise of calcium-based phosphate binders.
    Ortiz A; Sanchez-Niño MD
    Lancet; 2013 Oct; 382(9900):1232-4. PubMed ID: 23870814
    [No Abstract]   [Full Text] [Related]  

  • 13. ACP Journal Club. Review: non-calcium-based phosphate binders reduce mortality compared with calcium-based binders in CKD.
    Parikh CR
    Ann Intern Med; 2013 Nov; 159(10):JC2. PubMed ID: 24247692
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcium-based phosphate binders and chronic kidney disease.
    Hiremath S; Akbari A
    Lancet; 2014 Jan; 383(9913):216. PubMed ID: 24439735
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence of comparative effectiveness without evidence of effectiveness: the case of phosphate binders in CKD.
    Uhlig K
    Am J Kidney Dis; 2014 Jan; 63(1):13-5. PubMed ID: 24200463
    [No Abstract]   [Full Text] [Related]  

  • 16. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The contribution of dialysis and laboratoristic methods for the control of phosphates].
    Bolasco P
    G Ital Nefrol; 2014; 31(2):. PubMed ID: 24777923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
    Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA
    Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label use of phosphate binders in non-dialysis-dependent CKD.
    Winkelmayer WC; Chertow GM
    Am J Kidney Dis; 2010 Nov; 56(5):813-6. PubMed ID: 20970022
    [No Abstract]   [Full Text] [Related]  

  • 20. Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada.
    Weir MA; Jain AK; Gomes T; Juurlink DN; Mamdani M; Li L; Garg AX
    Am J Kidney Dis; 2011 Feb; 57(2):357-9. PubMed ID: 21251552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.